Rodman & Renshaw Upgrades Viropharma (VPHM) to Market Outperform

Rodman & Renshaw upgrades Viropharma (Nasdaq: VPHM) from Market Perform to Market Outperform. Price target $18.

Rodman analyst says, "We are upgrading our rating on ViroPharma to Market Outperform following the announcement on Friday that the FDA has approved Cinryze for the prophylactic treatment of hereditary angioedema (HAE). We are highly confident that following the approval of Cinryze, the merger agreement between ViroPharma and Lev Pharmaceuticals (Nasdaq: LEVP) will be consummated directly following the LEVP shareholder vote on October 21st."

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious infectious diseases.

You May Also Be Interested In

• UPDATE: Williams Financial Group Upgrades Semtech Corp. (SMTC) to Buy; Check Again...Quarter Was Fairly Strong
• Wedbush Downgrades Maxwell Technologies (MXWL) to Neutral; Elevated Competitive and Supply Chain Risks
• UPDATE: Nomura Securities Upgrades Central European Distribution (CEDC) to Neutral; Strategic Alliance with Russian Standard

Create E-mail Alert Related Categories

Upgrades

Related Entities

Rodman & Renshaw

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter